Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year